Arcturus Reports Positive ARCT-810 Phase 2 Data and Unveils 40x More Potent LUNAR 2.0 Platform
ARCT has more than doubled off its 52-week low of $5.5.
Summary
Arcturus reported encouraging interim Phase 2 data for ARCT-810 in OTC deficiency and introduced LUNAR 2.0, a next-generation mRNA delivery platform showing 40-fold higher protein expression in primates. FDA feedback supports integrating ARCT-2601 into the ongoing Phase 2 study by year-end.
Key Events · Product Development and Regulatory · ARCT
-
ARCT-810 Phase 2 Interim Data Positive
Across 8 participants, ARCT-810 was generally safe and well tolerated; all maintained normal ammonia levels and showed reduced glutamine, with the 0.5 mg/kg cohort achieving normal-range glutamine. Weight gain was observed in all participants.
-
LUNAR 2.0 Platform Delivers 40x Potency Gain
In non-human primate studies, LUNAR 2.0 demonstrated 40-fold higher hEPO expression versus LUNAR 1.0 and 38-fold higher hOTC expression versus ATX-95, enabling lower doses and shorter infusion times.
-
ARCT-2601 Integration by Year-End 2026
FDA Type C meeting feedback supports integrating ARCT-2601 into the ongoing ARCT-810 Phase 2 study; an IND filing is planned for 4Q 2026 with 3-6 patients ages 12+.
-
Pipeline Expansion into PKU and Gout
The potency of LUNAR 2.0 unlocks new liver disease programs including Phenylketonuria (PKU) and Gout, with preclinical data showing 6-7 day durability for PAH mRNA.
Analysis · ARCT · Life Sciences
Interim Phase 2 results for ARCT-810 in OTC deficiency show safety and biomarker improvements, and the company introduced a next-generation LUNAR 2.0 delivery platform with 40-fold higher expression in primates. FDA alignment was confirmed to integrate ARCT-2601 into the ongoing Phase 2 study by year-end, and expansion into PKU and Gout was announced. This is a major pipeline validation event for a company that recently reported a 93% revenue drop and near-doubled net loss — positive clinical data and a more potent platform directly address the core investment thesis around its mRNA liver therapeutics.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARCT was trading at $13.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $378M. The 52-week trading range was $5.50 to $24.17. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.